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A B S T R A C T
Available data support the notion that cannabinoids, whose therapeutic value is limited due to severe adverse
reactions, could be beneficial as adjunctive agents in the management of mood disorders. Polytherapy, which is
superior to monotherapy in the terms of effectiveness, usually requires lower doses of the individual compo-
nents. Therefore, the main objective of our study was to determine whether administration of cannabinoid (CB)
receptor ligands would enhance the antidepressant activity of atypical antidepressant drugs, i.e. agomelatine and
tianeptine. To evaluate the antidepressant-like potential of the tested combinations, the mouse forced swim test
(FST) and the tail suspension test (TST) were used. The HPLC method was applied to assess the brain levels of
agomelatine and tianeptine. Both behavioural tests demonstrated that per se an ineffective intraperitoneal dose
of oleamide (CB1 receptor agonist, 5 mg/kg) potentiated the anti-immobility activity of tianeptine (15 mg/kg),
whereas AM251 (CB1 receptor inverse agonist/antagonist, 0.25 mg/kg) enhanced the antidepressant effects of
tianeptine and agomelatine (20 mg/kg). Intraperitoneal co-administration of per se inactive doses of AM630
(CB2 receptor inverse agonist/antagonist) and agomelatine or tianeptine significantly reduced the immobility
time of animals only in the FST. CB receptor ligands did not affect the brain levels of the tested atypical anti-
depressants. In summary, the outcomes of the present study showed that activation and inhibition of CB1 re-
ceptors as well as inhibition of CB2 receptors may increase the antidepressant activity of tianeptine, whereas only
inhibition of CB1 and CB2 receptors has a potential to augment the antidepressant activity of agomelatine.
1. Introduction
Since augmentation and combining therapies have become a
common practice in management of the difficult-to-treat depression,
new treatment strategies are being searched for. Available data support
the notion that adjunctive use of agents modulating different neuro-
chemical pathways involved in depression with antidepressant drugs
may alleviate disease symptoms more profoundly than typical anti-
depressant monotherapy (Ceskova, 2016). Compounds with novel me-
chanisms of action are particularly under active investigation. Canna-
binoids, i.e. ligands of cannabinoid (CB) receptors, belong to these
substances. It was confirmed a long time ago that CB receptors play an
important role in regulation of the excitatory (glutamate-related) and
inhibitory (GABA-related) neurotransmissions in the brain as well as
they modulate synthesis and release of monoamines (i.e., dopamine,
norephinephrine, serotonin) (Moreira et al., 2009). Literature data also
provide reliable evidence that the endocannabinoid system interplays
with the hypothalamic–pituitary–adrenal axis, neuroplasticity markers
(i.e., the brain-derived neurotrophic factor, BDNF), immune system, or
acetylcholine pathways (McLaughlin et al., 2009; Moreira et al., 2009;
Zoppi et al., 2014; Kruk-Słomka et al., 2015). All of the above-men-
tioned signalings are implicated in the pathomechanism of depression.
Moreover, under certain conditions, CB receptor ligands display the
anxiolytic-like activity (Moreira et al., 2009) and they produce rapid
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behavioural responses (Linge et al., 2016). Unfortunately, both stimu-
lation and inhibition of the endocannabinoid system (particularly via
CB1 receptors) entail the development of severe adverse reactions (like
agitation, aggression, eating disorders, seizures, hypertension, emesis,
hypokalaemia) that limit the therapeutic value of CB receptor ligands in
monotherapy (Moreira and Crippa, 2009; Hermanns-Clausen et al.,
2013). However, CB receptor ligands are still regarded as compounds
with a huge therapeutical potential in polytherapy. Polytherapy, which
usually requires lower doses of the individual components, could be at
least equal to monotherapy in the terms of effectiveness.
Therefore, in the present study we decided to investigate whether
CB receptor ligands would enhance the antidepressant activity of aty-
pical antidepressant drugs, i.e. agomelatine and tianeptine. We selected
four diverse compounds that interplay differently with CB receptors: (i)
oleamide – an agonist of CB1 receptors, (ii) AM251 – an inverse agonist/
antagonist of CB1 receptors, (iii) JWH133 – an agonist of CB2 receptors,
and (iv) AM630 – an inverse agonist/antagonist of CB2 receptors.
Atypical antidepressants have unique pharmacological properties dis-
tinguished by more than one mode of action. In a certain sense, these
agents were developed in a response to problems with effectiveness and
safety profile of the monoamine based drugs. Biological effects of
agomelatine are related to close association between dysfunctions in
the circadian rhythms and symptoms of depression, and this multi-
modal agent agonizes the melatonin M1 and M2 receptors as well as it
antagonizes the serotoninergic 5-HT2B and 5-HT2C receptors. It also
modulates glutamatergic signaling, promotes hippocampal neurogen-
esis, and reduces neuroinflammation (Guardiola-Lemaitre et al., 2014;
Fasipe, 2019). As for tianeptine, the mechanisms of its antidepressant
action have not been fully described yet. It is known for sure that this
atypical drug neither influences the transporters for noradrenaline or
dopamine, nor binds to serotoninergic, dopaminergic, glutamatergic,
GABAergic, cholinergic, adrenergic, or histamine receptors. However, it
moderately augments the dopamine release via unknown pathways,
stabilizes the glutamatergic neurotransmission, increases the level of
α1-adrenoceptors, and most probably it potentiates functioning of
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) re-
ceptors. Additionally, tianeptine acts as an agonist of opioid μ receptors
(McEwen et al., 2010).
Scientific justification for carrying out the presented research was
based on our previous reports (Poleszak et al., 2019) as well as on the
findings of Takahashi et al. (2008) which demonstrated that CB re-
ceptor ligands are able to potentiate the activity of common anti-
depressant drugs that influence the monoaminergic neurotransmission.
Takahashi et al. (2008) showed that CB1 receptor antagonists
(SR141716A and AM251) produced an additive effect when adminis-
tered with selective serotonin reuptake inhibitors (citalopram or ser-
traline). We gave evidence that both CB1 receptor stimulation (by
oleamide) and inhibition (by AM251) augment the activity of imipra-
mine (a tricyclic antidepressant), escitalopram (a selective serotonin
reuptake inhibitor), and reboxetine (a norepinephrine reuptake in-
hibitor) (Poleszak et al., 2019). Thus, a combination of CB receptor
ligands and atypical antidepressant drugs also seemed to us as a pro-
mising treatment option. We were also encouraged by the fact that both
agomelatine and tianeptine are clinically used as a part of combined
therapy with standard antidepressant drugs, and such a polytherapy
seems to be a more favourable strategy than monotherapy, particularly
in the treatment-resistant cases (Tobe and Rybakowski, 2013; Fasipe,
2019; Potměšil, 2019).
2. Materials and methods
The experiments were carried out in accordance with binding law
related to studies on animal models as well as in compliance with the
protocol approved by the Local Ethics Committee.
2.1. Animals
Drug and test naïve adult male Albino Swiss mice (8–10 weeks old,
25–30 g) provided by the Centre for Experimental Medicine (OMD) at
the Medical University of Lublin were used in the study. Animals were
kept in standard cages (8 individuals/cage) in the environmentally
controlled facility, i.e. 12 h day/night cycle, temperature of 22–23 °C,
humidity of 45–55%, with free access to both water and food. The
bedding was corncob granules and it was changed once a week. The
refinement principle minimizing potential distress and enhancing an-
imal welfare was applied. Overall 356 mice were randomly assigned to
experimental groups. Each testing group was represented by 7–10 an-
imals, depending on the research schedule. All behavioural experiments
were performed between 8:00 and 15:00.
2.2. Drugs
The following agents were tested in the study: (i) CB1 receptor li-
gands – oleamide (cis-9,10-octadecenoamide, Tocris, USA) and AM251
(N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-
1H-pyrazole-3-carboxamide, Tocris, USA), (ii) CB2 receptor ligands –
JWH133 ((6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro-
6,6,9-trimethyl-6H-dibenzo[b,d]pyran, Tocris, USA) and AM630 (6-
Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methox-
yphenyl)methanone, Tocris, USA), and (iii) atypical antidepressants –
agomelatine (Sigma-Aldrich, USA) and tianeptine (Sigma-Aldrich,
USA). The CB receptor ligands and agomelatine were suspended in an
aqueous solution of Tween 80 (1%), whereas tianeptine was dissolved
in saline. Prepared suspensions and the solution were given as in-
traperitoneal (ip) injections: agomelatine and tianeptine – 60 min be-
fore testing, and oleamide, AM251, JWH133, and AM630 – 30 min
before testing. The control animals received ip injections of vehicles, i.e.
saline and the aqueous solution of Tween 80 (1%). The tested doses as
well as the pretreatment schedules were chosen on the basis of the
results of our previous projects (e.g., Szopa et al., 2019) and the lit-
erature data (Kruk-Słomka et al., 2015).
The following experimental groups were tested:
(i) the control group that received vehicles, i.e. saline + aqueous
solution of Tween 80 (1%)
(ii) animals that received oleamide (5 mg/kg) + saline
(iii) animals that received AM251 (0.25 mg/kg) + saline
(iv) animals that received JWH133 (0.25 mg/kg) + saline
(v) animals that received AM630 (0.25 mg/kg) + saline
(vi) animals that received agomelatine (20 mg/kg) + saline
(vii) animals that received tianeptine (15 mg/kg) + aqueous solution
of Tween 80 (1%)
(viii) animals that received oleamide (5 mg/kg) + agomelatine
(20 mg/kg)
(ix) animals that received oleamide (5 mg/kg) + tianeptine (15 mg/
kg)
(x) animals that received AM251 (0.25 mg/kg) + agomelatine
(20 mg/kg)
(xi) animals that received AM251 (0.25 mg/kg) + tianeptine (15 mg/
kg)
(xii) animals that received JWH133 (0.25 mg/kg) + agomelatine
(20 mg/kg)
(xiii) animals that received JWH133 (0.25 mg/kg) + tianeptine
(15 mg/kg)
(xiv) animals that received AM630 (0.25 mg/kg) + agomelatine
(20 mg/kg)
(xv) animals that received AM630 (0.25 mg/kg) + tianeptine (15 mg/
kg)
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2.3. Forced swim test (FST)
The FST was carried out according to the procedure described by
Porsolt et al. (1977). Briefly, each mouse was placed individually into a
glass cylinder (height 25 cm, diameter 10 cm) containing 10 cm of
water at 23–25 °C. An animal was left there for 6 min. Immobility of a
mouse, i.e. duration of time when a given animal stopped struggling in
the water and performed only movements necessary to keep its head
over the water surface, was measured between the 2nd and the 6th min
of the test.
2.4. Tail suspension test (TST)
The TST was carried out according to the procedure described by
Steru et al. (1985). Each mouse was suspended by the tail (2 cm from
the end of the tail) about 50 cm above the floor, using an adhesive tape.
It was left there for 6 min. Immobility of animals, i.e. duration of time
when a suspended mouse stopped struggling in the air and performed
only movements necessary to breathe, was measured between the 2nd
and the 6th min of the test.
2.5. Spontaneous locomotor activity
Measurements of spontaneous locomotor activity was carried out
according to the procedure we had used before (Szopa et al., 2019). An
activity meter Opto-Varimex-4 Auto-Track (Columbus Instruments,
USA) was used. The device consists of 4 transparent cages with lids
equipped with 4 infrared emitters with laser beams and 4 detectors
monitoring animal movements. Each mouse was placed individually
into the cage (43 cm × 43 cm × 32 cm) and left there for 6 min. A
distance travelled by a given animal was recorded automatically during
the time interval corresponding to the one analyzed in the FST and the
TST, that is between the 2nd and the 6th min of the test.
2.6. Determination of the brain levels of agomelatine and tianeptine
60 min following injection of a given atypical antidepressant (with
or without a CB receptor ligand), the tested animals were decapitated
and their brains were collected and frozen. The brain levels of ago-
melatine and tianeptine were assessed by the high-performance liquid
chromatography (HPLC) method, according to the procedure we had
used before (Szopa et al., 2019). The brains were homogenized in dis-
tilled water (1:4, w/v) with a TH220 tissue homogenizer (Omni Inter-
national, Inc., Warrenton, VA, USA). For agomelatine, 1 ml of brain
homogenate was spiked with carbamazepine (100 ng/ml) as an internal
standard (IS). Before the extraction, 1 ml of the concentrated NaCl
solution (10 g/50 ml) was added to brain homogenate and the samples
were vortexed for 15 s. The extraction of agomelatine from brain
homogenate was performed using 5 ml of a mixture of di-
chloromethane/hexane/isoamyl alcohol (39.5:59.5:1 v/v/v). The sam-
ples were shaken for 20 min and centrifuged for 15 min at 1000 ×g.
After the centrifugation, the organic layers were transferred into conical
glass tubes and evaporated to dryness at 37 °C under a gentle stream of
nitrogen in a water bath. The residues were dissolved with 100 μl of
methanol, and aliquots of 50 μl were injected into the HPLC system.
Carbamazepine (250 ng/ml) was also used as IS for tianeptine. 10 μl of
this solution was added to the brain homogenate (1 ml) containing
tianeptine. 1 ml of phosphate buffer (0.5 M, pH 7.0) was given to the
samples. Next, the samples were extracted with 3 ml of the extraction
reagent, i.e. a mixture of ethyl acetate/hexane (30:70, v/v), by shaking
for 20 min (IKA Vibrax VXR, Germany). After centrifugation at
3000 rpm for 15 min (Universal 32, Hettich, Germany), the organic
layers were transferred into conical glass tubes and evaporated to
dryness at 37 °C under a gentle stream of nitrogen in a water bath. The
residues were dissolved with 100 μl of methanol, and aliquots of 50 μl
were injected into the HPLC system.
The HPLC system consisted of an isocratic pump (model L-7100)
and an autosampler (model L-7200), both from Merck Hitachi
(Darmstadt, Germany), and a UV variable-wavelength K-2600 detector
(Knauer, Berlin, Germany). Data acquisition and processing were car-
ried out using the D-7000 HSM software (Merck Hitachi). Analysis of
agomelatine and tianeptine was performed on a 250 × 4 mm
LiChrospher1100 RP-18 column with a particle size of 5 μm (Merck,
Darmstadt, Germany) protected with a guard column (4 × 4 mm) with
the same packing material. The mobile phase consisting of acetonitrile
and 50 mM potassium dihydrogen phosphate was mixed at a ratio of
37:63 (v/v) for agomelatine and 31:69 (v/v) for tianeptine and run at
1 ml/min. Chromatographic analysis was carried out at 21 °C and an
analytical wavelength of 230 nm for agomelatine and 214 nm for tia-
neptine.
The calibration curves constructed by plotting the ratio of the peak
heights of the studied drug to IS versus the concentration of the drug
were linear in the tested concentration ranges. No interfering peaks
were observed in the chromatograms. The measurements were re-
producible with low intra- and interday variation (coefficient of var-
iation<10%). The extraction efficiencies of the analyzed compounds
and the internal standard ranged from 70% to 95%. Levels of the tested
antidepressants were given in ng/g (for the wet brain tissue).
2.7. Statistical analysis
Statistical analysis was performed either by two-way analysis of
variance (ANOVA) with Bonferroni's post-hoc test or by t-test, de-
pending on the study design. The results from the behavioural tests
were calculated by two-way ANOVA, whereas the outcomes from the
pharmacokinetic analyses were calculated by t-test. In two-way
ANOVA, the following independent variables were taken into con-
sideration: (i) treatment with an atypical antidepressant, and (ii)
treatment with a CB receptor ligand. The results were presented as the
means± standard error of the mean (SEM). Between-group differences
with p lower than 0.05 were treated as statistically significant (where:
*p < 0.05, **p < 0.01, and ***p < 0.001).
3. Results
An acute ip injection of oleamide (5 mg/kg), AM251 (0.25 mg/kg),
JWH133 (0.25 mg/kg), AM630 (0.25 mg/kg), agomelatine (20 mg/kg),
or tianeptine (15 mg/kg) did not change the immobility time of the
tested mice in the FST and in the TST, when compared to the vehicle-
treated group.
3.1. Effects of a concomitant administration of oleamide and the atypical
antidepressants in the FST and the TST
As presented in Fig. 1, an acute injection of oleamide (5 mg/kg) did
not potentiate the activity of agomelatine given at a dose of 20 mg/kg
either in the FST or in the TST. Though Bonferroni's post-hoc test de-
tected significant differences in the FST between the group that re-
ceived oleamide + agomelatine and the group that received only
agomelatine, two-way ANOVA demonstrated a non-significant olea-
mide-agomelatine interaction in the FST [F(1,35) = 1.07; p = 0.3074]
and also a non-significant oleamide-agomelatine interaction in the TST
[F(1,36) = 1.03; p = 0.3178]. On the other hand, oleamide managed
to augment the anti-immobility effect of tianeptine (15 mg/kg) in both
applied tests. Statistical analysis by two-way ANOVA confirmed a sig-
nificant oleamide-tianeptine interaction in the FST [F(1,34) = 5.68;
p = 0.0229] with a significant effect of oleamide [F(1,34) = 18.72;
p = 0.0001] and a significant effect of tianeptine [F(1,34) = 6.01;
p = 0.0195]. Similarly, two-way ANOVA demonstrated a significant
oleamide-tianeptine interaction in the TST [F(1,36) = 17.43;
p = 0.0002] with a significant effect of oleamide [F(1,36) = 10.71;
p = 0.0024] and a significant effect of tianeptine [F(1,36) = 12.21;
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p = 0.0013].
3.2. Effects of a concomitant administration of AM251 and the atypical
antidepressants in the FST and the TST
After combined administration of AM251 (0.25 mg/kg) and ago-
melatine (20 mg/kg) or tianeptine (15 mg/kg), the tested mice strug-
gled for a longer time when placed in the water or suspended by their
tails in comparison to the animals that were given the respective
monotherapy (Fig. 2). Two-way ANOVA revealed: (1) a significant
AM251-agomelatine interaction [F(1,28) = 5.61; p = 0.0250] in the
FST, with a significant effect of AM251 [F(1,28) = 23.29; p < 0.0001]
and a significant effect of agomelatine [F(1,28) = 8.61; p = 0.0066],
(2) a significant AM251-agomelatine interaction [F(1,26) = 8.23;
p = 0.0081] in the TST, with a significant effect of agomelatine [F
(1,26) = 5.75; p = 0.0240] but a not significant effect of AM251 [F
(1,26) = 0.91; p = 0.3499], (3) a significant AM251-tianeptine inter-
action [F(1,26) = 4.33; p= 0.0475] in the FST, with a significant effect
of AM251 [F(1,26) = 9.06; p = 0.0057] and a significant effect of
tianeptine [F(1,26) = 20.64; p = 0.0001], (4) a significant AM251-
tianeptine interaction [F(1,28) = 11.40; p= 0.0022] in the TST, with a
significant effect of tianeptine [F(1,28) = 26.95; p < 0.0001] but a
not significant effect of AM251 [F(1,28) = 2.17; p = 0.1521].
3.3. Effects of a concomitant administration of JWH133 and the atypical
antidepressants in the FST and the TST
Addition of JWH133 (0.25 mg/kg) to the treatment with agomela-
tine (20 mg/kg) or tianeptine (15 mg/kg) did not potentiate the activity
of the tested atypical antidepressants in either of the applied tests. The
animals that received JWH133 + agomelatine or
JWH133 + tianeptine behaved almost in the same manner in the FST
and in the TST as the mice that received only JWH133 or the respective
antidepressant drug. Though Bonferroni's post-hoc test detected sig-
nificant differences in the FST between the group that received
JWH133 + tianeptine and the groups that received only JWH133 or
the vehicle, two-way ANOVA did not detect any significant drug-drug
interaction for the JWH133-tianeptine treatment in the FST (F
(1,28) = 1.03; p= 0.3182) or in the TST (F(1,28) = 1.02; p=0.3211).
Similarly, a non-significant interaction was obtained for the JWH133-
agomelatine treatment in the FST (F(1,28) = 2.73; p = 0.1094) and in
the TST (F(1,28) = 0.08; p = 0.7846). The results were illustrated in
Fig. 3.
Fig. 1. Effect of a concurrent intraperitoneal administration of oleamide and
atypical antidepressants in (A) the FST and (B) the TST in mice.
Oleamide (5 mg/kg) was given 30 min before the experiment, while agome-
latine (20 mg/kg) and tianeptine (15 mg/kg) were injected 60 min before
testing. The values represent mean + SEM (n = 9–10 animals per group).
^^p < 0.01, ^^^p < 0.01 versus respective antidepressant drug; ##p < 0.01,
###p < 0.001 versus oleamide; *p < 0.05, ***p < 0.001 versus vehicle
(two-way ANOVA followed by Bonferroni's post-hoc test).
Fig. 2. Effect of a concurrent intraperitoneal administration of AM251 and
atypical antidepressants in (A) the FST and (B) the TST in mice.
AM251 (0.25 mg/kg) was given 30 min before the experiment, while agome-
latine (20 mg/kg) and tianeptine (15 mg/kg) were injected 60 min before
testing. The values represent mean + SEM (n = 7–8 animals per group).
^p < 0.05, ^^p < 0.01, ^^^p < 0.01 versus respective antidepressant drug;
##p < 0.01, ###p < 0.001 versus AM251; ***p < 0.001 versus vehicle
(two-way ANOVA followed by Bonferroni's post-hoc test).
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3.4. Effects of a concomitant administration of AM630 and the atypical
antidepressants in the FST and the TST
Mice that received a combination of AM630 (0.25 mg/kg) and
agomelatine (20 mg/kg) or tianeptine (15 mg/kg) were actively moving
for a longer time in the FST in comparison to animals from the control
groups. Such an effect was not observed in the TST – mice treated with
a given concomitant therapy stayed immobile for a similar duration of
time as the animals subjected to the respective monotherapy (Fig. 4).
Calculations with two-way ANOVA showed a significant AM630-ago-
melatine interaction [F(1,28) = 13.26; p = 0.0011] in the FST, with a
significant effect of AM630 [F(1,28) = 14.32; p = 0.0007] and a sig-
nificant effect of agomelatine [F(1,28) = 7.05; p = 0.0129], but a not
significant AM630-agomelatine interaction [F(1,28) = 3.45;
p = 0.0736] in the TST. Correspondingly, according to the statistical
outcomes, AM630-tianeptine interaction in the FST was significant [F
(1,27) = 4.98; p = 0.0341], with a significant effect of both AM630 [F
(1,27) = 5.75; p = 0.0237] and tianeptine [F(1,27) = 7.19;
p = 0.0124], but it was not significant in the TST [F(1,28) = 1.67;
p = 0.2071].
3.5. Effects of a concomitant administration of the CB receptor ligands and
the atypical antidepressants on the spontaneous locomotor activity of mice
None of the tested agents (i.e., oleamide, AM251, JWH133, AM630,
agomelatine, and tianeptine) or their respective combinations sig-
nificantly increased the spontaneous locomotor activity of mice
(Table 1).
3.6. Brain levels of agomelatine and tianeptine
In the statistical analysis of outcomes from the pharmacokinetic
assay, we took into consideration only these combinations that had
acted synergistically in the behavioural tests, i.e. AM251 (0.25 mg/kg)
or AM630 (0.25 mg/kg) with agomelatine (20 mg/kg), and oleamide (5
mg/kg), AM251, or AM630 with tianeptine (15 mg/kg). As presented in
Table 2, none of the tested CB receptor ligands increased or reduced the
brain levels of the atypical antidepressants. Calculations with t-test gave
the following results: (1) t(14) = 0.1431, p = 0.8882 for the AM251-
agomelatine combination, (2) t(13) = 1.895, p = 0.0806 for the
AM630-agomelatine combination, (3) t(18) = 0.4003, p = 0.6937 for
the oleamide-tianeptine combination, (4) t(14) = 1.104, p = 0.2882
for the AM251-tianeptine combination, and (5) t(14) = 0.8493,
p = 0.4100 for the AM630-tianeptine combination.
Fig. 3. Effect of a concurrent intraperitoneal administration of JWH133 and
atypical antidepressants in (A) the FST and (B) the TST in mice.
JWH133 (0.25 mg/kg) was given 30 min before the experiment, while ago-
melatine (20 mg/kg) and tianeptine (15 mg/kg) were injected 60 min before
testing. The values represent mean + SEM (n = 8 animals per group).
#p < 0.05 versus JWH133; **p < 0.01 versus vehicle (two-way ANOVA
followed by Bonferroni's post-hoc test).
Fig. 4. Effect of a concurrent intraperitoneal administration of AM630 and
atypical antidepressants in (A) the FST and (B) the TST in mice.
AM630 (0.25 mg/kg) was given 30 min before the experiment, while agome-
latine (20 mg/kg) and tianeptine (15 mg/kg) were injected 60 min before
testing. The values represent mean + SEM (n = 7–8 animals per group).
^^p < 0.01, ^^^p < 0.01 versus respective antidepressant drug; ##p < 0.01,
###p < 0.001 versus AM630; **p < 0.01, ***p < 0.001 versus vehicle (two-
way ANOVA followed by Bonferroni's post-hoc test).
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4. Discussion
To the best of our knowledge this is the first report of a positive
interaction between CB1 and CB2 receptor ligands and atypical anti-
depressant drugs in the FST and the TST in mice. Activity of tianeptine
(15 mg/kg) was potentiated by opposing pharmacological interventions
towards CB1 receptors, i.e. by administration of per se ineffective doses
of their agonist (oleamide, 5 mg/kg) and inverse agonist/antagonist
(AM251, 0.25 mg/kg). We demonstrated that the antidepressant effect
of tianeptine was also augmented by per se an inactive dose of the in-
verse agonist/antagonist of CB2 receptors (AM630, 0.25 mg/kg),
whereas it was not affected by the CB2 receptor agonist (JWH133,
0.25 mg/kg). As for the activity of agomelatine, it was enhanced only
by inhibition of either CB1 or CB2 receptor functioning. Stimulation of
CB1 or CB2 receptors had no impact on the antidepressant potential of
this drug. We should also underline that positive interactions between
the CB1 or CB2 receptor antagonists and the tested antidepressants were
definitely more pronounced in the FST than in the TST. Differences in
the sensitivity of the tests were particularly noticed in the case of
AM630, since only the FST detected significant AM630-agomelatine
and AM630-tianeptine interactions. According to outcomes obtained in
the TST, these substances did not mutually potentiate each other's ac-
tivity when given in the respective combinations. Following Cryan et al.
(2005), the FST and the TST may respond differently to a given drug,
and antidepressant-like effects of some atypical agents can be detected
in the swimming test but not seen in the suspension test, as it happened
in our study. Despite several reports that cannabinoids may change the
spontaneous motility of rodents (Onaivi et al., 2008; Kruk-Słomka et al.,
2015), neither hyperkinesia nor hypolocomotion confounded our re-
sults in the FST and the TST. Animals from all tested groups travelled
the same distance as their vehicle-treated counterparts. Furthermore,
the introduced treatment was well tolerated by the mice since they did
not manifest any visible signs of health deterioration.
The outcomes of our experiments are partially in line with the well-
known bi-directional activity of the CB1 receptor-related signaling.
Generally, the endocannabinoid system and its regulatory mechanisms
appear to be highly complicated and complex. On the one hand, the
dampened endocannabinoid-dependent signaling is related to the de-
pression-like phenotype (Smaga et al., 2017) and its stimulation via CB1
receptors activation, inhibition of fatty acid amide hydrolase (i.e., an
endogenous enzyme that breaks down anandamide), or via reduction of
endocannabinoid uptake has an antidepressant-like potential
(Adamczyk et al., 2008; Bambico et al., 2010). On the other hand, in-
verse agonists/antagonists of CB1 receptors (such as AM251 or rimo-
nabant) also exert anti-immobility effects in the FST (Shearman et al.,
2003; Griebel et al., 2005; Kruk-Słomka et al., 2015) and the TST
(Shearman et al., 2003; Khakpai et al., 2019) in rodents. Similarly, both
CB2 receptor agonists (e.g. JWH133) and inverse agonists/antagonists
(e.g. AM630) have displayed the antidepressant-like activity in the re-
cognized behavioural tests (García-Gutiérrez et al., 2010; Kruk-Słomka
et al., 2015; Khakpai et al., 2019). Furthermore, there are reports of the
pro-depressive effects induced by the enhancement of the en-
docannbinoid signaling (Pertwee, 2015). The dual action of the en-
docannabinoid system has been detected for the anxiolytic-like/anxio-
genic effects, as well. In fact, it is difficult to say why agonists and
antagonists of CB1 and CB2 receptors can have the same activity in the
FST and the TST. Some authors (Häring et al., 2013) assume that the
specific localization of CB receptors could be one of the reasons for the
contradictory outcomes from the pre-clinical studies focused on the role
of the endocannabinoid system in the pathogenesis of anxiety and de-
pression. CB1 receptors are localized in GABA-ergic (i.e., inhibitory)
and glutamatergic (i.e., excitatory) terminals, thus they have at the
same time an impact on the opposing neurotransmissions. Other au-
thors suggest that several other factors may contribute to the final
outcomes, such as: (1) an animal model/strain, their baseline stress
level, experimental conditions, or an applied dose of a given cannabi-
noid (e.g., Griebel et al., 2005; Bambico et al., 2010; Beyer et al., 2010),
(2) existence of the functional pools of receptors that are involved in
manifestation of the depressogenic and antidepressant effects (Patel
and Hillard, 2009), and (3) the existence of some unknown subtypes of
endocannabinoid receptors (Ostadhadi et al., 2016).
Literature data clearly indicate that CB1 receptors directly and in-
directly modulate the monoaminergic system. They are present on both
serotonin and norepinephrine neurons in diverse parts of the brain as
well as they can be found in limbic mood-regulatory areas rich in do-
pamine. It has been demonstrated that CB1 receptor ligands influence
the firing of monoaminergic neurons and have an impact on the dopa/
dopamine, norepinephrine, and serotonin synthesis as well as on do-
pamine, norepinephrine, serotonin, glutamate, and GABA release in
specific brain regions (Esteban and García-Sevilla, 2012). As for CB2
Table 1
Effect of a combined intraperitoneal administration of (A) oleamide, (B)
AM251, (C) JWH133, or (D) AM630 and atypical antidepressant drugs on the
spontaneous locomotor activity of mice.
Treatment (n = number of mice per group) Travelled distance (cm)
(A) Vehicle + vehicle (n = 8) 662.6 ± 42.78
Oleamide + vehicle (n = 8) 511.5 ± 83.66
Agomelatine + vehicle (n = 8) 530.1 ± 83.95
Agomelatine + oleamide (n = 7) 420.9 ± 59.87
Tianeptine + vehicle (n = 8) 594.8 ± 77.18
Tianeptine + oleamide (n = 7) 382.0 ± 80.17
(B) Vehicle + vehicle (n = 8) 629.0 ± 82.22
AM251 + vehicle (n = 8) 647.6 ± 47.97
Agomelatine + vehicle (n = 8) 674.9 ± 37.73
Agomelatine + AM251 (n = 8) 560.6 ± 32.65
Tianeptine + vehicle (n = 8) 720.6 ± 130.3
Tianeptine + AM251 (n = 8) 856.9 ± 74.32
(C) Vehicle + vehicle (n = 8) 585.6 ± 49.79
JWH133 + vehicle (n = 8) 567.0 ± 53.30
Agomelatine + vehicle (n = 8) 561.5 ± 48.07
Agomelatine + JWH133 (n = 8) 555.9 ± 40.16
Tianeptine + vehicle (n = 8) 565.6 ± 103.5
Tianeptine + JWH133 (n = 8) 561.3 ± 72.00
(D) Vehicle + vehicle (n = 8) 402.0 ± 82.89
AM630 + vehicle (n = 8) 544.9 ± 34.57
Agomelatine + vehicle (n = 8) 407.8 ± 73.66
Agomelatine + AM630 (n = 8) 545.9 ± 65.85
Tianeptine + vehicle (n = 8) 536.6 ± 101.4
Tianeptine + AM630 (n = 8) 681.5 ± 138.9
Oleamide (5 mg/kg), AM251 (0.25 mg/kg), JWH133 (0.25 mg/kg), and AM630
(0.25 mg/kg) were given 30 min before the experiment, while agomelatine
(20 mg/kg) and tianeptine (15 mg/kg) were injected 60 min before testing. The
values represent mean ± SEM (two-way ANOVA followed by Bonferroni's post-
hoc test).
Table 2
Effects of CB receptor ligands on the brain levels of atypical antidepressants in
mice.
Treatment Drug level in the brain (ng/g) Number of animals
per group
Agomelatine + vehicle 9.204 ± 2.080 8
Agomelatine + AM251 8.850 ± 1.336 8
Agomelatine + vehicle 13.77 ± 3.859 7
Agomelatine + AM630 6.056 ± 1.785 8
Tianeptine + vehicle 37.83 ± 5.605 10
Tianeptine + oleamide 35.14 ± 3.735 10
Tianeptine + vehicle 10.18 ± 0.9068 8
Tianeptine + AM251 14.74 ± 4.033 8
Tianeptine + vehicle 16.32 ± 2.566 8
Tianeptine + AM630 12.15 ± 4.186 8
Oleamide (5 mg/kg), AM251 (0.25 mg/kg), and AM630 (0.25 mg/kg) were
administered intraperitoneally 30 min before decapitation, whereas tianeptine
(15 mg/kg) and agomelatine (20 mg/kg) were injected intraperitoneally 60 min
before decapitation. The values represent mean ± SEM (t-test).
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receptor ligands, modulation of the serotonin-, glutamate-, immune-,
and/or neurotrophin-related pathways may be involved in their anti-
depressant-like activity (Benito et al., 2008; García-Gutiérrez et al.,
2010; Zoppi et al., 2014; Ishiguro et al., 2018). Therefore, we assume
that the enhancement of the serotoninergic neurotransmission may be
particularly responsible for the observed interactions between CB re-
ceptor ligands and agomelatine, whereas potentiation of the dopami-
nergic signaling may be mainly responsible for the positive interplay
between CB receptor ligands and tianeptine. Keeping in mind that
AM630 is not only an inverse agonist/antagonist of CB2 receptors but it
also has an affinity towards CB1 receptors and it acts as their inverse
agonist (Landsman et al., 1998), one can suspect that an interplay be-
tween AM630 and CB1 receptors can contribute to the final effects of
AM630 treatment in our studies. We guess that co-administration of
oleamide and agomelatine as well as concurrent use of JWH133 and
agomelatine or tianeptine were unable to sufficiently increase the levels
of monoamines, and this is the reason why these combinations did not
induce shortening of the immobility time of animals in the applied
behavioural tests. Of note is the fact that the antidepressant activity of
agomelatine is partially due to the inhibition of serotoninergic 5-HT2A
receptors, whereas in studies by Franklin et al. (2013) JWH133 has
emerged as an agent that upregulates these receptors. So, the opposite
activity towards serotoninergic 5-HT2A receptors may be responsible for
the lack of the antidepressant potential of the JWH133-agomelatine
combination.
Drug-drug interactions detected in our study are most probably due
to mechanisms that take place at the cellular level, since our pharma-
cokinetic studies did not reveal significant alterations in the brain levels
of the tested atypical antidepressants after concomitant administration
with CB receptor ligands. Based on the outcomes of Smaga et al. (2017),
an acute administration of tianeptine could have increased CB1 density
in different parts of the brain, including the motor cortex, frontal
cortex, and hippocampus. However, we should not expect an intensified
expression of CB1 and CB2 receptors in the hippocampus, frontal cortex
and/or prefrontal cortex – such effects were detected only after chronic,
not acute, treatment with tianeptine (10 mg/kg).
We think that the main limitation of the current study is lack of
experiments assessing the brain levels of neurotransmitters involved in
the development of depression. In fact, we are going to carry out such
analyses in future projects, since they would enable better under-
standing of the molecular mechanisms implicated in the interplay be-
tween the endocannabinoid system and antidepressant drugs.
Moreover, without running an isobologram analysis we are not able to
conclude whether the drug combinations used in our studies produced
additive or synergistic effects.
5. Conclusions
To the best of our knowledge this is the first report of a positive
interaction between CB1 and CB2 receptor ligands and atypical anti-
depressant drugs in the FST and the TST in mice. Accordingly, the
following outcomes of the presented experiments should be particularly
emphasized: (1) both activation and inhibition of CB1 receptors as well
as inhibition of CB2 receptors may increase the antidepressant activity
of tianeptine, (2) inhibition of CB1 and CB2 receptors has a potential to
augment the antidepressant activity of agomelatine, (3) the observed
interactions have rather the pharmacodynamic background instead of
the pharmacokinetic one.
These preliminary findings need to be confirmed in further experi-
ments, but it seems that the adjuvant therapy to atypical anti-
depressants based on modulation of the endocannabinoid system
(particularly via CB1 receptors) could be a promising treatment option.
Such a strategy may be beneficial in patients suffering from depression
that co-exists with anxiety, since CB receptor ligands, agomelatine, and
tianeptine have a certain anxiolytic potential (Pertwee, 2015; Brink
et al., 2006; McEwen et al., 2010; Fasipe, 2019).
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